Financial Results for the quarter and half year ended September 30,2025
ALPA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 7.4 pts less than Nifty Microcap 250 and 6.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Alpa Laboratories reported standalone revenue from operations of ₹2,563 lacs for Q2 FY26, up modestly from ₹2,494 lacs in Q2 FY25 (~2.8% YoY). H1 FY26 revenue came in at ₹4,474 lacs, down about 3.5% from ₹4,638 lacs in H1 FY25. Profit after tax collapsed sharply to just ₹5.76 lacs in Q2 FY26 versus ₹762.81 lacs in Q2 FY25, with H1 FY26 PAT at ₹187.93 lacs versus ₹277.03 lacs in H1 FY25 (~32% decline). The Q2 weakness was largely driven by the absence of a deferred tax credit that boosted the year-ago quarter; no exceptional items were recorded this quarter. The statutory auditor (C.H. Padliya & Co.) issued an unqualified limited review report on both standalone and consolidated results. Operating cash flow remained healthy at ₹1,215 lacs for H1 standalone, and the balance sheet shows minimal leverage with only ₹234 lacs of short-term borrowings against other equity of over ₹17,263 lacs.
Despite stable top-line numbers, the sharp Q2 PAT slump is likely to weigh on investor sentiment and could put short-term pressure on the stock. The company's overall financials, cash generation, and balance sheet remain sound, so the weakness looks more like a one-quarter tax-driven distortion than a structural problem.